{"id":808,"date":"2025-02-18T09:51:01","date_gmt":"2025-02-18T09:51:01","guid":{"rendered":"http:\/\/wmtc2006.com\/?p=808"},"modified":"2025-02-18T09:51:01","modified_gmt":"2025-02-18T09:51:01","slug":"as-of-the-cutoff-day-october-1-2019-154-individuals-had-received-the-treatment-and-125-of-them-were-evaluated-for-ttnt","status":"publish","type":"post","link":"https:\/\/wmtc2006.com\/?p=808","title":{"rendered":"\ufeffAs of the cutoff day (October 1, 2019), 154 individuals had received the treatment and 125 of them were evaluated for TTNT"},"content":{"rendered":"<p>\ufeffAs of the cutoff day (October 1, 2019), 154 individuals had received the treatment and 125 of them were evaluated for TTNT. [1, 2]. The goal of treatment for newly diagnosed, Evocalcet transplant-eligible patients is definitely to achieve the best depth of remission and improve the progression-free survival (PFS) and overall survival (OS). The consensus is definitely that induction therapy followed by autologous stem cell transplantation (ASCT) and maintenance therapy should be the overall management of myeloma, while the quality of life, tolerability, duration of treatment, convenience, and patients preference are taken into account [3]. For individuals eligible for ASCT, three to four cycles <a href=\"https:\/\/www.adooq.com\/evocalcet.html\">Evocalcet<\/a> of induction therapy are generally needed before the mobilization of hematopoietic stem cells. Proteasome inhibitors (PIs) and immunomodulator medicines (IMiDs)-centered triplet regimens are preferentially regarded as, such as bortezomib (BTZ) and lenalidomide (Len) plus dexamethasone (DEX) (VRD), BTZ and thalidomide plus DEX (VTD), or cyclophosphamide and BTZ plus DEX (CyBorD). With better depth of remission and survival [4C6], VRD is currently a standard regimen. The quadruplet routine of BTZ, Len, cyclophosphamide, and DEX has been found to have improved hematological toxicity but related efficacy compared to the triplet regimens [7]. Furthermore, with the wide software of cytogenetics-based stratification requirements, clinical trials are generally recommended to high-risk individuals with the Evocalcet presence of del(17p), translocation t(4;14), t(14;16), t(14;20), 1q21 amplification or p53 mutation; or main plasma cell leukemia; or the presence of 5 to 20% circulating plasma cells and extramedullary disease. Individuals with more than one of the high-risk cytogenetic features are considered to have an ultra-high-risk disease. Based on the encouraging data from randomized tests [8, 9], the MAYO 2020 mSMART guideline recommended induction therapy with monoclonal antibodyCbased daratumumab (D)-VRD routine for cytogenetically high-risk individuals [10]. For individuals ineligible for transplantation, the goal is to accomplish deep remission without any serious adverse effects (AEs). Elderly individuals who are often complicated with different comorbidities and various impairment of cognitive, physical, and interpersonal functions should be thoroughly evaluated before induction therapy. For fit individuals, VRD is recommended for initial therapy followed by maintenance therapy with Len, or a BTZ-based routine for high-risk individuals. Daratumumab and Len plus DEX (DRD) is an alternative that has been recently authorized for long-term treatment. In the new drug era, the part of ASCT is still irreplaceable, particularly for individuals with high-risk cytogenetic features [11]. ASCT <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?db=gene&#038;cmd=Retrieve&#038;dopt=full_report&#038;list_uids=10683\">DLL3<\/a> could improve the depth of response, MRD-negativity rate, and PFS, but its benefit in OS needs further evaluation with longer observation time and more instances [12]. However, no consensus has been reached regarding the time for ASCT (early ASCT following induction therapy versus delayed ASCT after relapse) in individuals having a standard-risk [12, 13]. Allogeneic hematopoietic stem cell transplant is definitely hardly ever regarded as, but is applicable for young individuals with high-risk cytogenetics. The significance of the second ASCT is definitely unclear. Hence, more prospective, randomized tests are needed to clarify this in relapsed and refractory MM (RRMM). Progression of disease is very common even when a complete remission (CR) has been accomplished after ASCT. It is important to accomplish MRD negativity through maintenance therapy to prolong the response period and PFS without inducing severe AEs. Len is generally recommended Evocalcet for maintenance therapy [14, 15], and BTZ as well [16, 17], especially in individuals with high-risks (e.g., del17p). Studies investigating the response to maintenance therapy with monoclonal antibodies are ongoing. Based on the benefit in PFS shown in the TOURMALINE-MM3 (NCT02181413) study [18], ixazomib, a novel PI, has been included like a category A recommendation in NCCN recommendations for maintenance therapy in transplant-eligible individuals with newly diagnosed MM (NDMM). Though the period of maintenance therapy is still controversial, increasing evidence offers suggested that it should be made the decision relating to MRD status. Currently, the treatment strategies for RRMM are based on the different mixtures of standard medicines and novel medicines,.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\ufeffAs of the cutoff day (October 1, 2019), 154 individuals had received the treatment and 125 of them were evaluated for TTNT. [1, 2]. The [&#8230;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[28],"tags":[],"class_list":["post-808","post","type-post","status-publish","format-standard","hentry","category-hepatocyte-growth-factor-receptors"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\ufeffAs of the cutoff day (October 1, 2019), 154 individuals had received the treatment and 125 of them were evaluated for TTNT - Discovery and characterization of Histamine-2 Receptor Antagonists<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/wmtc2006.com\/?p=808\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\ufeffAs of the cutoff day (October 1, 2019), 154 individuals had received the treatment and 125 of them were evaluated for TTNT - Discovery and characterization of Histamine-2 Receptor Antagonists\" \/>\n<meta property=\"og:description\" content=\"\ufeffAs of the cutoff day (October 1, 2019), 154 individuals had received the treatment and 125 of them were evaluated for TTNT. [1, 2]. The [...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/wmtc2006.com\/?p=808\" \/>\n<meta property=\"og:site_name\" content=\"Discovery and characterization of Histamine-2 Receptor Antagonists\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-18T09:51:01+00:00\" \/>\n<meta name=\"author\" content=\"wpadmin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpadmin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/wmtc2006.com\\\/?p=808#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/wmtc2006.com\\\/?p=808\"},\"author\":{\"name\":\"wpadmin\",\"@id\":\"http:\\\/\\\/wmtc2006.com\\\/#\\\/schema\\\/person\\\/5a1d916d8ed9c89b34ac45c96f81e776\"},\"headline\":\"\ufeffAs of the cutoff day (October 1, 2019), 154 individuals had received the treatment and 125 of them were evaluated for TTNT\",\"datePublished\":\"2025-02-18T09:51:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/wmtc2006.com\\\/?p=808\"},\"wordCount\":648,\"articleSection\":[\"Hepatocyte Growth Factor Receptors\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/wmtc2006.com\\\/?p=808\",\"url\":\"https:\\\/\\\/wmtc2006.com\\\/?p=808\",\"name\":\"\ufeffAs of the cutoff day (October 1, 2019), 154 individuals had received the treatment and 125 of them were evaluated for TTNT - Discovery and characterization of Histamine-2 Receptor Antagonists\",\"isPartOf\":{\"@id\":\"http:\\\/\\\/wmtc2006.com\\\/#website\"},\"datePublished\":\"2025-02-18T09:51:01+00:00\",\"author\":{\"@id\":\"http:\\\/\\\/wmtc2006.com\\\/#\\\/schema\\\/person\\\/5a1d916d8ed9c89b34ac45c96f81e776\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/wmtc2006.com\\\/?p=808#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/wmtc2006.com\\\/?p=808\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/wmtc2006.com\\\/?p=808#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"http:\\\/\\\/wmtc2006.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\ufeffAs of the cutoff day (October 1, 2019), 154 individuals had received the treatment and 125 of them were evaluated for TTNT\"}]},{\"@type\":\"WebSite\",\"@id\":\"http:\\\/\\\/wmtc2006.com\\\/#website\",\"url\":\"http:\\\/\\\/wmtc2006.com\\\/\",\"name\":\"Discovery and characterization of Histamine-2 Receptor Antagonists\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"http:\\\/\\\/wmtc2006.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"http:\\\/\\\/wmtc2006.com\\\/#\\\/schema\\\/person\\\/5a1d916d8ed9c89b34ac45c96f81e776\",\"name\":\"wpadmin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e57206ca88c051844b618224f501afdd8e9328b238000fd2f37bf30c03bcff14?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e57206ca88c051844b618224f501afdd8e9328b238000fd2f37bf30c03bcff14?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e57206ca88c051844b618224f501afdd8e9328b238000fd2f37bf30c03bcff14?s=96&d=mm&r=g\",\"caption\":\"wpadmin\"},\"sameAs\":[\"http:\\\/\\\/wmtc2006.com\"],\"url\":\"https:\\\/\\\/wmtc2006.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\ufeffAs of the cutoff day (October 1, 2019), 154 individuals had received the treatment and 125 of them were evaluated for TTNT - Discovery and characterization of Histamine-2 Receptor Antagonists","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/wmtc2006.com\/?p=808","og_locale":"en_US","og_type":"article","og_title":"\ufeffAs of the cutoff day (October 1, 2019), 154 individuals had received the treatment and 125 of them were evaluated for TTNT - Discovery and characterization of Histamine-2 Receptor Antagonists","og_description":"\ufeffAs of the cutoff day (October 1, 2019), 154 individuals had received the treatment and 125 of them were evaluated for TTNT. [1, 2]. The [...]","og_url":"https:\/\/wmtc2006.com\/?p=808","og_site_name":"Discovery and characterization of Histamine-2 Receptor Antagonists","article_published_time":"2025-02-18T09:51:01+00:00","author":"wpadmin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"wpadmin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/wmtc2006.com\/?p=808#article","isPartOf":{"@id":"https:\/\/wmtc2006.com\/?p=808"},"author":{"name":"wpadmin","@id":"http:\/\/wmtc2006.com\/#\/schema\/person\/5a1d916d8ed9c89b34ac45c96f81e776"},"headline":"\ufeffAs of the cutoff day (October 1, 2019), 154 individuals had received the treatment and 125 of them were evaluated for TTNT","datePublished":"2025-02-18T09:51:01+00:00","mainEntityOfPage":{"@id":"https:\/\/wmtc2006.com\/?p=808"},"wordCount":648,"articleSection":["Hepatocyte Growth Factor Receptors"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/wmtc2006.com\/?p=808","url":"https:\/\/wmtc2006.com\/?p=808","name":"\ufeffAs of the cutoff day (October 1, 2019), 154 individuals had received the treatment and 125 of them were evaluated for TTNT - Discovery and characterization of Histamine-2 Receptor Antagonists","isPartOf":{"@id":"http:\/\/wmtc2006.com\/#website"},"datePublished":"2025-02-18T09:51:01+00:00","author":{"@id":"http:\/\/wmtc2006.com\/#\/schema\/person\/5a1d916d8ed9c89b34ac45c96f81e776"},"breadcrumb":{"@id":"https:\/\/wmtc2006.com\/?p=808#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/wmtc2006.com\/?p=808"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/wmtc2006.com\/?p=808#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"http:\/\/wmtc2006.com\/"},{"@type":"ListItem","position":2,"name":"\ufeffAs of the cutoff day (October 1, 2019), 154 individuals had received the treatment and 125 of them were evaluated for TTNT"}]},{"@type":"WebSite","@id":"http:\/\/wmtc2006.com\/#website","url":"http:\/\/wmtc2006.com\/","name":"Discovery and characterization of Histamine-2 Receptor Antagonists","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"http:\/\/wmtc2006.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"http:\/\/wmtc2006.com\/#\/schema\/person\/5a1d916d8ed9c89b34ac45c96f81e776","name":"wpadmin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e57206ca88c051844b618224f501afdd8e9328b238000fd2f37bf30c03bcff14?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e57206ca88c051844b618224f501afdd8e9328b238000fd2f37bf30c03bcff14?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e57206ca88c051844b618224f501afdd8e9328b238000fd2f37bf30c03bcff14?s=96&d=mm&r=g","caption":"wpadmin"},"sameAs":["http:\/\/wmtc2006.com"],"url":"https:\/\/wmtc2006.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/wmtc2006.com\/index.php?rest_route=\/wp\/v2\/posts\/808","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wmtc2006.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wmtc2006.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wmtc2006.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/wmtc2006.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=808"}],"version-history":[{"count":1,"href":"https:\/\/wmtc2006.com\/index.php?rest_route=\/wp\/v2\/posts\/808\/revisions"}],"predecessor-version":[{"id":809,"href":"https:\/\/wmtc2006.com\/index.php?rest_route=\/wp\/v2\/posts\/808\/revisions\/809"}],"wp:attachment":[{"href":"https:\/\/wmtc2006.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=808"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wmtc2006.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=808"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wmtc2006.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=808"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}